Forzani & Macphail Colon Cancer Screening Centre, University of Calgary
Calgary, Alberta, T2N 4N1, Canada
Location status: Recruiting
NCT Number: NCT05396560
This is an observational study in a clinical setting to estimate the prevalence of advanced colorectal neoplasia (ACN) at colonoscopy in those with a history of low or high risk polyps or a family history of CRC/polyps and to verify the test performance characteristics of FIT in these populations. Using this information, a risk prediction model will be developed to help guide the choice between FIT and colonoscopy in the ongoing surveillance or screening of patients.
Interested in participating?
Request Info18 year–74 year
All sexes
Observational
Calgary, Alberta, T2N 4N1, Canada
Location status: Recruiting
Colonoscopy is an effective tool in reducing colorectal cancer (CRC) incidence, however, it is a limited resource that is not without risk. The overall goal of this study is to determine if Fecal Immunochemical Tests (FIT) could be an effective alternative to colonoscopy for the surveillance of patients at increased risk for CRC. The rationale for this project is that colonoscopy is both a more expensive (30-40X) and more limited resource than FIT, which because of its pivotal role in the investigation and management of many gastrointestinal conditions is constantly in demand.
Routine post-polypectomy surveillance is placing a rapidly growing demand on existing colonoscopy resources, driven in part by the rapid expansion of CRC screening programs.(1) Currently, there are not strong contemporary data to guide the use of colonoscopy or alternative tests for the surveillance of patients after the removal of low or high risk polyps, but colonoscopy is routinely recommended by screening guidelines, as historically no other reasonable options existed. Colonoscopy screening is also the default recommendation for individuals with a family history of CRC or polyps.
It is proposed that the highly sensitive and low cost FIT could replace colonoscopy for post-polypectomy surveillance and primary screening in at least some patients and, thereby, reduce costs while improving access to colonoscopy for other patients.
The following knowledge gaps must be filled prior to advocating the use of FIT for post-polypectomy surveillance or primary screening:
This is an observational study conducted in a clinical setting to estimate the prevalence of advanced colorectal neoplasia (ACN) at colonoscopy in those with a history of low or high risk polyps or a family history of CRC/polyps and to verify the test performance characteristics of FIT in these populations. Using this information, a risk prediction model will be developed to help guide the choice between FIT and colonoscopy in the ongoing surveillance or screening of patients.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At time of colonoscopy
ACN: Colorectal cancer or an advanced adenoma (> 1 cm, villous features, high grade dysplasia) or serrated polyp (> 1 cm or any conventional dysplasia).
Time frame: FIT test to be completed between 3-42 days prior to participant colonoscopy
Single fecal sample for measurement of hemoglobin using the OC-Sensor FIT. Positive if measured hemoglobin is ≥100 ng/ml (manufacturers recommended cut off).
Sensitivity = proportion of individuals with at least one ACN who had a positive FIT.
Specificity = proportion of individuals without advanced lesions who had a negative FIT.
Interested in participating?
Request InfoUniversity of Calgary
Other
Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy (FIT2RUN Study)
Acronym: FIT2RUN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06750094
Colonic Diseases, Colorectal Neoplasms
Chandler, Arizona, United States
View Trial DetailsNCT06663319
Colonic Diseases, Colorectal Neoplasms
Aurora, Colorado, United States
View Trial DetailsNCT06662786
Colonic Diseases, Colorectal Neoplasms
Gilbert, Arizona, United States
View Trial DetailsNCT07299071
Colonic Diseases, Colonoscopy
Bayonne, France
View Trial Details